Hikma Expands In Canada With Four New Injectables
All Four Sterile Injectables Represent First Or Second Generic Versions In Canadian Market
Hikma has bolstered its generic sterile injectables business in Canada with four new launches.
You may also be interested in...
Hikma has passed a milestone with its US injectables portfolio after the latest trio of launches.
Quickfire M&A has been unveiled in Canada, with Juno Pharmaceuticals taking control of the former Nichi-Iko affiliate Omega Laboratories.
As expected, Hikma’s generics business saw a significant slide in 2022 – but contributions from its successful injectables and brands divisions helped to stop an overall sales decline for the firm.